Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Blood Advances|April 1, 2021
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cellsElina Parri, Heikki Kuusanmäki, Daria Bulanova, et al.
Molecular Systems Biology|March 19, 2020
Improved detection of differentially represented DNA barcodes for high-throughput clonal phenomicsYevhen Akimov, Daria Bulanova, Sanna Timonen, et al.
STAR Protocols|February 24, 2026
Protocol for generating an in vitro 3D multicellular culture model of ovarian high-grade serous carcinomaKrister Wennerberg, Daria Bulanova, Laura Gall-Mas, et al.
NAR Cancer|June 16, 2023
Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinomaJan Benada, Daria Bulanova, Violette Azzoni, et al.
Scientific Reports|June 18, 2016
BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanineYuexi Gu, Mikko Helenius, Kristiina Väänänen, et al.
Leukemia|July 12, 2020
Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibitionMahesh Tambe, Ella Karjalainen, Markus Vähä-Koskela, et al.
Science Advances|May 23, 2024
A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cellsDaria Bulanova, Yevhen Akimov, Wojciech Senkowski, et al.
EMBO Molecular Medicine|March 3, 2020
Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancerLidia Moyano-Galceran, Elina A Pietilä, S Pauliina Turunen, et al.
Briefings in Bioinformatics|August 3, 2021
Network-guided identification of cancer-selective combinatorial therapies in ovarian cancerLiye He, Daria Bulanova, Jaana Oikkonen, et al.
Nature Communications|October 3, 2024
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clonesAleksandr Ianevski, Kristen Nader, Kyriaki Driva, et al.
Pageof 2